Senator Bernie Sanders
Although GLP-1 weight-loss drugs are delivering impressive results, the big concern is the high price of treatment – and who pays for it. Sen. Bernie Sanders, I-Vt., has weighed in on the debate by calling on Novo Nordisk to lower the price of its popular drugs Ozempic and Wegovy, and wants to meet with the drugmakers's CEO Lars Fruergaard Jorgensen over the costs of GLP-1 drugs for diabetes and obesity.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
